Shopping Cart 0
Cart Subtotal
USD 0

Cancer Genetics Inc (CGIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Cancer Genetics Inc (CGI) is a pharmaceutical company that provides diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic information to healthcare professionals, biopharma companies, and cancer centers. CGI provides clinical services such as expand DX, test menu, complete program, and summation report. The company offers a range of pharmacogenomics testing services for clinical oncologists, cancer centers, and research institutions, and for biotech and biopharma customers. It works in research collaboration with cancer centers to develop and validate proprietary tests. CGI is headquartered in Rutherford, New Jersey, the US.

Cancer Genetics Inc (CGIX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cancer Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cancer Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

PierianDx Enters into Agreement with Cancer Genetics 13

Cancer Genetics Enters into Partnership with Indian Cooperative Oncology Network 14

Gentris to Enter into Agreement with Shanghai Institutes of Preventive Medicine 15

Cancer Genetics Enters into Agreement with Lantern Pharma 16

Cancer Genetics Enters into Agreement with Biotech and Pharma Companies 17

Cancer Genetics Enters into Agreement with BeiGene 18

Cancer Genetics Enters into Co-Marketing Agreement with Bio Analytical Research 19

Cancer Genetics Partners with H3 Biomedicine 20

Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 21

Mayo Clinic Forms Joint Venture With Cancer Genetics 22

Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 24

Gentris Enters Into Co-Development With Shanghai Institutes of Preventive Medicine 25

Merger 26

NovellusDx to Merge with Cancer Genetics 26

Licensing Agreements 28

Cancer Genetics Enters into Licensing Agreement with Cleveland Clinic Foundation 28

Equity Offering 29

Cancer Genetics Prices USD7 Million in Private Placement of Units 29

Cancer Genetics Raises USD3 Million in First Tranche of Private Placement of Shares 30

Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 31

Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 32

Cancer Genetics Raises USD12 Million in Public Offering of Shares 33

Debt Offering 35

Cancer Genetics Raises USD2.6 Million in Private Placement of 10% Notes Due 2019 35

Acquisition 36

ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36

Cancer Genetics to Acquire vivoPharm for USD12 Million 37

Cancer Genetics Acquires Gentris for USD4.75 Million 38

Cancer Genetics Inc-Key Competitors 39

Cancer Genetics Inc-Key Employees 40

Cancer Genetics Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Joint Venture 42

Recent Developments 43

Strategy And Business Planning 43

Sep 20, 2018: Cancer Genetics and NovellusDx agree to merge 43

Financial Announcements 44

Aug 14, 2018: Cancer Genetics announces second quarter 2018 financial results 44

May 15, 2018: Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates 46

Apr 02, 2018: Cancer Genetics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Strategic Business Updates 48

Nov 09, 2017: Cancer Genetics Reports Record Third Quarter 2017 Revenue and 134% Increase in Contracted Bookings from Major Biotech and Pharmaceutical Companies 50

Aug 14, 2017: Cancer Genetics Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise 52

May 11, 2017: Cancer Genetics Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability 54

Mar 23, 2017: Cancer Genetics Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update 56

Corporate Communications 58

Jun 12, 2018: Cancer Genetics Appoints Michael McCartney As Chief Commercial Officer 58

Feb 05, 2018: Cancer Genetics Announces Resignation Of Panna Sharma As Chief Executive Officer 59

Nov 27, 2017: Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors 60

Legal and Regulatory 61

May 06, 2018: Kaskela Law: Shareholder Class Action Filed Against Cancer Genetics 61

Product News 62

Dec 11, 2017: Cancer Genetics Advances Understanding of Immune Response and Measurement in Lymphomas by Combining PD-L1 Expression Analysis With RNA Analysis 62

Other Significant Developments 63

Jan 06, 2017: Cancer Genetics Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions 63

Appendix 64

Methodology 64

About GlobalData 64

Contact Us 64

Disclaimer 64


List Of Figure

List of Figures

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cancer Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cancer Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cancer Genetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cancer Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

PierianDx Enters into Agreement with Cancer Genetics 13

Cancer Genetics Enters into Partnership with Indian Cooperative Oncology Network 14

Gentris to Enter into Agreement with Shanghai Institutes of Preventive Medicine 15

Cancer Genetics Enters into Agreement with Lantern Pharma 16

Cancer Genetics Enters into Agreement with Biotech and Pharma Companies 17

Cancer Genetics Enters into Agreement with BeiGene 18

Cancer Genetics Enters into Co-Marketing Agreement with Bio Analytical Research 19

Cancer Genetics Partners with H3 Biomedicine 20

Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 21

Mayo Clinic Forms Joint Venture With Cancer Genetics 22

Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 24

Gentris Enters Into Co-Development With Shanghai Institutes of Preventive Medicine 25

NovellusDx to Merge with Cancer Genetics 26

Cancer Genetics Enters into Licensing Agreement with Cleveland Clinic Foundation 28

Cancer Genetics Prices USD7 Million in Private Placement of Units 29

Cancer Genetics Raises USD3 Million in First Tranche of Private Placement of Shares 30

Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 31

Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 32

Cancer Genetics Raises USD12 Million in Public Offering of Shares 33

Cancer Genetics Raises USD2.6 Million in Private Placement of 10% Notes Due 2019 35

ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36

Cancer Genetics to Acquire vivoPharm for USD12 Million 37

Cancer Genetics Acquires Gentris for USD4.75 Million 38

Cancer Genetics Inc, Key Competitors 39

Cancer Genetics Inc, Key Employees 40

Cancer Genetics Inc, Other Locations 41

Cancer Genetics Inc, Subsidiaries 41

Cancer Genetics Inc, Joint Venture 42

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cancer Genetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cancer Genetics Inc (CGI) is a pharmaceutical company that provides diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic information to healthcare professionals, biopharma companies, and cancer centers. CGI provides clinical services such as expand DX, test menu, complete program, and summation report. The company offers a range of pharmacogenomics testing services for clinical oncologists, cancer centers, and research institutions, and for biotech and biopharma customers. It works in research collaboration with cancer centers to develop and validate proprietary tests. CGI is headquartered in Rutherford, New Jersey, the US.

Cancer Genetics Inc (CGIX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cancer Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cancer Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

PierianDx Enters into Agreement with Cancer Genetics 13

Cancer Genetics Enters into Partnership with Indian Cooperative Oncology Network 14

Gentris to Enter into Agreement with Shanghai Institutes of Preventive Medicine 15

Cancer Genetics Enters into Agreement with Lantern Pharma 16

Cancer Genetics Enters into Agreement with Biotech and Pharma Companies 17

Cancer Genetics Enters into Agreement with BeiGene 18

Cancer Genetics Enters into Co-Marketing Agreement with Bio Analytical Research 19

Cancer Genetics Partners with H3 Biomedicine 20

Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 21

Mayo Clinic Forms Joint Venture With Cancer Genetics 22

Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 24

Gentris Enters Into Co-Development With Shanghai Institutes of Preventive Medicine 25

Merger 26

NovellusDx to Merge with Cancer Genetics 26

Licensing Agreements 28

Cancer Genetics Enters into Licensing Agreement with Cleveland Clinic Foundation 28

Equity Offering 29

Cancer Genetics Prices USD7 Million in Private Placement of Units 29

Cancer Genetics Raises USD3 Million in First Tranche of Private Placement of Shares 30

Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 31

Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 32

Cancer Genetics Raises USD12 Million in Public Offering of Shares 33

Debt Offering 35

Cancer Genetics Raises USD2.6 Million in Private Placement of 10% Notes Due 2019 35

Acquisition 36

ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36

Cancer Genetics to Acquire vivoPharm for USD12 Million 37

Cancer Genetics Acquires Gentris for USD4.75 Million 38

Cancer Genetics Inc-Key Competitors 39

Cancer Genetics Inc-Key Employees 40

Cancer Genetics Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Joint Venture 42

Recent Developments 43

Strategy And Business Planning 43

Sep 20, 2018: Cancer Genetics and NovellusDx agree to merge 43

Financial Announcements 44

Aug 14, 2018: Cancer Genetics announces second quarter 2018 financial results 44

May 15, 2018: Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates 46

Apr 02, 2018: Cancer Genetics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Strategic Business Updates 48

Nov 09, 2017: Cancer Genetics Reports Record Third Quarter 2017 Revenue and 134% Increase in Contracted Bookings from Major Biotech and Pharmaceutical Companies 50

Aug 14, 2017: Cancer Genetics Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise 52

May 11, 2017: Cancer Genetics Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability 54

Mar 23, 2017: Cancer Genetics Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update 56

Corporate Communications 58

Jun 12, 2018: Cancer Genetics Appoints Michael McCartney As Chief Commercial Officer 58

Feb 05, 2018: Cancer Genetics Announces Resignation Of Panna Sharma As Chief Executive Officer 59

Nov 27, 2017: Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors 60

Legal and Regulatory 61

May 06, 2018: Kaskela Law: Shareholder Class Action Filed Against Cancer Genetics 61

Product News 62

Dec 11, 2017: Cancer Genetics Advances Understanding of Immune Response and Measurement in Lymphomas by Combining PD-L1 Expression Analysis With RNA Analysis 62

Other Significant Developments 63

Jan 06, 2017: Cancer Genetics Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions 63

Appendix 64

Methodology 64

About GlobalData 64

Contact Us 64

Disclaimer 64


List Of Figure

List of Figures

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cancer Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cancer Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cancer Genetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cancer Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

PierianDx Enters into Agreement with Cancer Genetics 13

Cancer Genetics Enters into Partnership with Indian Cooperative Oncology Network 14

Gentris to Enter into Agreement with Shanghai Institutes of Preventive Medicine 15

Cancer Genetics Enters into Agreement with Lantern Pharma 16

Cancer Genetics Enters into Agreement with Biotech and Pharma Companies 17

Cancer Genetics Enters into Agreement with BeiGene 18

Cancer Genetics Enters into Co-Marketing Agreement with Bio Analytical Research 19

Cancer Genetics Partners with H3 Biomedicine 20

Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 21

Mayo Clinic Forms Joint Venture With Cancer Genetics 22

Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 24

Gentris Enters Into Co-Development With Shanghai Institutes of Preventive Medicine 25

NovellusDx to Merge with Cancer Genetics 26

Cancer Genetics Enters into Licensing Agreement with Cleveland Clinic Foundation 28

Cancer Genetics Prices USD7 Million in Private Placement of Units 29

Cancer Genetics Raises USD3 Million in First Tranche of Private Placement of Shares 30

Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 31

Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 32

Cancer Genetics Raises USD12 Million in Public Offering of Shares 33

Cancer Genetics Raises USD2.6 Million in Private Placement of 10% Notes Due 2019 35

ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36

Cancer Genetics to Acquire vivoPharm for USD12 Million 37

Cancer Genetics Acquires Gentris for USD4.75 Million 38

Cancer Genetics Inc, Key Competitors 39

Cancer Genetics Inc, Key Employees 40

Cancer Genetics Inc, Other Locations 41

Cancer Genetics Inc, Subsidiaries 41

Cancer Genetics Inc, Joint Venture 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cancer Genetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.